HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.

American Headache Society Annual Scientific Meeting

The American Headache Society (AHS) Annual Scientific Meeting is designed for physicians, psychologists, scientists, researchers, physician assistants, nurse practitioners, and other health professionals involved in the care of patients with head, neck, and orofacial pain. It aims to disseminate the most up-to-date research and scientific advances underlying the practice of headache medicine.

The Treatment of Status Migrainosus in Emergency Care Settings: Matthew Robbins, MD

July 20, 2022

The neurologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital offered his insight into the state of treatment for status migrainosus and whether or not the new migraine medications can help improve care. [WATCH TIME: 2 minutes]

State of Migraine Care and Therapeutics: Richard B. Lipton, MD

July 13, 2022

The director of the Montefiore Headache Center provided an overview of the recent advances in migraine medications and how it has translated to improved care. [WATCH TIME: 2 minutes]

Advantages in Adding Intranasal Zavagepant to the Migraine Treatment Landscape: Richard B. Lipton, MD

July 11, 2022

The director of the Montefiore Headache Center provided commentary on how analyses presented at AHS 2022 further support the benefits intranasal zavagepant bring to the migraine treatment landscape. [WATCH TIME: 5 minutes]

Efficacy, Safety of Rimegepant When Used Both as Preventively and As-Need: Richard B. Lipton, MD

July 10, 2022

The director of the Montefiore Headache Center provided insight on an open-label study presented at AHS 2022 that highlighted rimegepant’s (Nurtec ODT; Biohaven) impact both as a preventative and acute medication. [WATCH TIME: 5 minutes]

Understanding the Impact of MiCOAS Qualitative Study: Richard B. Lipton, MD

July 08, 2022

The director of the Montefiore Headache Center discussed the intuitiveness and advantages the Migraine Clinical Outcome Assessment System, or MiCOAS, grant provides to clinical trials and patients with migraine. [WATCH TIME: 5 minutes]

Advocating for Patients With Migraine Through Research Initiatives: Serena L. Orr, MD, MSc

July 07, 2022

The pediatric neurologist and headache specialist at the University of Calgary and Alberta Children’s Hospital spoke about the need for improved funding and research efforts for the migraine population. [WATCH TIME: 5 minutes]

Episode 67: Mental Health and Advocacy in Pediatric Migraine

July 01, 2022

Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Serena L. Orr, MD, MSc.

AHS 2022: Top Interviews and Key Takeaways

June 29, 2022

The NeurologyLive® team assembled some of the best discussions with leaders in headache and migraine medicine following the 2022 American Headache Society (AHS) Annual Scientific Meeting.

Number and Severity of Cranial Autonomic Symptoms Differ Based on Cluster Headache, Migraine Aura Status

June 18, 2022

On average, those with cluster headache had 4.8 cranial autonomic symptoms compared with 2.7 for those with migraine, regardless of aura status.

Patient-Reported Outcomes Favor Erenumab Over Topiramate for Migraine in HER-MES Study

June 16, 2022

Over a 24-week treatment period, 72.2% of those on erenumab achieved relevant improvement on HIT-6 scores compared with 53.9% of those on topiramate.